The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation

Published:2018-06-27 Issue:8 Volume:32 Page:1787-1794
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Fein Joshua A.,Shimoni Avichai,Labopin Myriam,Shem-Tov Noga,Yerushalmi Ronit,Magen Hila,Furie Nadav,Kopel Eli,Danylesko Ivetta,Nagler Arnon,Shouval Roni

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0185-y.pdf

Reference30 articles.

1. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.

2. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.

3. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

4. Potdar R, Varadi G, Fein J, Labopin M, Nagler A, Shouval R. Prognostic scoring systems in allogeneic hematopoietic stem cell transplantation: where do we stand? Biol Blood Marrow Transplant. 2017;23:1839–46.

5. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation;Bone Marrow Transplantation;2024-08-13

2. Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation;Transplantation and Cellular Therapy;2024-08

3. Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia;Bone Marrow Transplantation;2024-07-12

4. Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation;American Journal of Hematology;2024-05-14

5. Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review;Journal of Geriatric Oncology;2024-04